| Title | Publication Date | Language | Citations |
|---|---|---|---|
| The biosimilar approval process: how different is it? | 2017/10/01 | English | 24 |
| Biosimilars: considerations for clinical practice | 2017/10/01 | English | 16 |
| Interleukin 6: The biology behind the therapy | 2018/11/01 | English | 8 |
| Considering new lessons about the use of IL-6 inhibitors in arthritis | 2018/11/01 | English | 4 |
| Targeting IL-6: A review of data | 2018/11/01 | English | 4 |
| Biosimilars already approved and in development | 2017/10/01 | English | 4 |
| IL-6: To immunity and beyond | 2018/11/01 | English | |
| Considering IL-6 | 2018/11/01 | English | |
| Considering biosimilars in inflammatory diseases | 2017/10/01 | English | |
| Considerations in Medicine | 2017/10/01 | English | |
| Considering biosimilar policy | 2017/10/01 | English |